@article{43e53c39db8146729bf4f3dfa17709e7,
title = "A classification approach to estimating human circadian phase under circadian alignment from actigraphy and photometry data",
abstract = "The time of dim light melatonin onset (DLMO) is the gold standard for circadian phase assessment in humans, but collection of samples for DLMO is time and resource-intensive. Numerous studies have attempted to estimate circadian phase from actigraphy data, but most of these studies have involved individuals on controlled and stable sleep-wake schedules, with mean errors reported between 0.5 and 1 hour. We found that such algorithms are less successful in estimating DLMO in a population of college students with more irregular schedules: Mean errors in estimating the time of DLMO are approximately 1.5-1.6 hours. We reframed the problem as a classification problem and estimated whether an individual's current phase was before or after DLMO. Using a neural network, we found high classification accuracy of about 90%, which decreased the mean error in DLMO estimation—identifying the time at which the switch in classification occurs—to approximately 1.3 hours. To test whether this classification approach was valid when activity and circadian rhythms are decoupled, we applied the same neural network to data from inpatient forced desynchrony studies in which participants are scheduled to sleep and wake at all circadian phases (rather than their habitual schedules). In participants on forced desynchrony protocols, overall classification accuracy dropped to 55%-65% with a range of 20%-80% for a given day; this accuracy was highly dependent upon the phase angle (ie, time) between DLMO and sleep onset, with the highest accuracy at phase angles associated with nighttime sleep. Circadian patterns in activity, therefore, should be included when developing and testing actigraphy-based approaches to circadian phase estimation. Our novel algorithm may be a promising approach for estimating the onset of melatonin in some conditions and could be generalized to other hormones.",
keywords = "actigraphy, biological clocks, circadian rhythm, classification, machine learning, melatonin, shift-work",
author = "Brown, {Lindsey S.} and {St. Hilaire}, {Melissa A.} and McHill, {Andrew W.} and Phillips, {Andrew J.K.} and Barger, {Laura K.} and Akane Sano and Czeisler, {Charles A.} and Doyle, {Francis J.} and Klerman, {Elizabeth B.}",
note = "Funding Information: LSB, AWM, and FJD declare no conflicts of interest. MSH declares no conflicts of interest directly related to the study; she has provided paid limited consulting for The MathWorks, Inc (Natick, MA, USA) and she was paid by the Fund for Scientific Research – FNRS (Belgium) for a grant review. AJKP is an investigator on projects supported by the CRC for Alertness, Safety, and Productivity, and he has received research funding from Versalux and Delos. LKB was on the scientific board of CurAegis and received funding from Puget Sound Pilots and Boston Children's Hospital. AS has received travel reimbursement or honorarium payments from Gordon Research Conferences, Pola Chemical Industries, Leuven Mindgate, American Epilepsy Society, IEEE, and Association for the Advancement of Artificial Intelligence. She has received research support from Microsoft, Sony Corporation, NEC Corporation, and POLA chemicals, and consulting fees from Gideon Health and Suntory Global Innovation Center. EBK has received travel reimbursement from the Sleep Research Society, the National Sleep Foundation, the Santa Fe Institute, the World Conference of Chronobiology, the Gordon Research Conference, and the German Sleep Society (DGSM); she was paid by the Puerto Rico Trust for a grant review, and has consulted for the National Sleep Foundation and Sanofi‐Genzyme. CAC reports grants to BWH from FAA, NHLBI, NIA, NIOSH, NASA, and DOD; is/was a paid consultant to Emory University, Inselspital Bern, Institute of Digital Media and Child Development, Klarman Family Foundation, Physician's Seal, Sleep Research Society Foundation, Tencent Holdings Ltd, Teva Pharma Australia, and Vanda Pharmaceuticals Inc, in which Dr Czeisler also holds an equity interest; received travel support from Bloomage International Investment Group, Inc, UK Biotechnology and Biological Sciences Research Council, Bouley Botanical, Dr Stanley Ho Medical Development Foundation, European Biological Rhythms Society, German National Academy of Sciences (Leopoldina), National Safey Council, National Sleep Foundation, Stanford Medical School Alumni Association, Tencent Holdings Ltd, and Vanda Pharmaceuticals Inc; receives research/education support through BWH from Cephalon, Mary Ann & Stanley Snider via Combined Jewish Philanthropies, Harmony Biosciences LLC, Jazz Pharmaceuticals PLC Inc, Johnson & Johnson, NeuroCare, Inc, Philips Respironics Inc/Philips Homecare Solutions, Regeneron Pharmaceuticals, Regional Home Care, Teva Pharmaceuticals Industries Ltd, Sanofi SA, Optum, ResMed, San Francisco Bar Pilots, Sanofi, Schneider, Simmons, Sysco, Philips, Vanda Pharmaceuticals; is/was an expert witness in legal cases, including those involving Advanced Power Technologies, Aegis Chemical Solutions LLC, Amtrak; Casper Sleep Inc, C&J Energy Services, Dallas Police Association, Enterprise Rent‐A‐Car, Espinal Trucking/Eagle Transport Group LLC/Steel Warehouse Inc, FedEx, Greyhound Lines Inc/Motor Coach Industries/FirstGroup America, PAR Electrical Contractors Inc, Product & Logistics Services LLC/Schlumberger Technology Corp/Gelco Fleet Trust, Puckett Emergency Medical Services LLC, Union Pacific Railroad, and Vanda Pharmaceuticals; serves as the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc; and receives royalties from McGraw Hill, and Philips Respironics for the Actiwatch‐2 and Actiwatch Spectrum devices. CAC's interests were reviewed and are managed by the Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict of interest policies. Funding Information: This work was supported by NIH T32-HL007901 (LSB, AWM), R01GM105018, R00HL119618 (AJKP), K24HL105664 (EBK), K01HL146992 (AWM), P01AG009975 (CAC, EBK), and F32DK107146 (AWM), R21-NR018974 (MSH); Harvard Catalyst and NIH 1UL1TR001102 | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102); MIT Media Lab Consortium, Samsung Electronics, and NEC Corporation (AS); NASA 80NSSC20K0576 (MSH). LKB was supported in part by 2R01AG044416-06 and 1R01OH011773. Funding Information: This work was supported by NIH T32‐HL007901 (LSB, AWM), R01GM105018, R00HL119618 (AJKP), K24HL105664 (EBK), K01HL146992 (AWM), P01AG009975 (CAC, EBK), and F32DK107146 (AWM), R21‐NR018974 (MSH); Harvard Catalyst and NIH 1UL1TR001102 | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102); MIT Media Lab Consortium, Samsung Electronics, and NEC Corporation (AS); NASA 80NSSC20K0576 (MSH). LKB was supported in part by 2R01AG044416‐06 and 1R01OH011773. Publisher Copyright: {\textcopyright} 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2021",
month = aug,
doi = "10.1111/jpi.12745",
language = "English (US)",
volume = "71",
journal = "Journal of Pineal Research",
issn = "0742-3098",
publisher = "Wiley-Blackwell",
number = "1",
}